• :::Home
  • HK Technologies
  • Long COVID Test: [Non-Invasive Stool Test to detect distinct gut microbiome profile associated with “Long COVID”]

Long COVID Test: [Non-Invasive Stool Test to detect distinct gut microbiome profile associated with “Long COVID”]

MagIC
Overview

We have identified for the first-time distinct gut microbiome profiles associated with post-acute COVID-19 syndrome, more commonly known as “long COVID”. 

These distinct gut microbial signatures can be used to predict the risk of developing long COVID and diagnose long COVID in patients with persistent symptoms after the acute infection. This is the world’s first study to demonstrate the gut microbiota as a key determinant of long COVID

  • Long COVID Test: [Non-Invasive Stool Test to detect distinct gut microbiome profile associated with “Long COVID”] 0
Technical name of innovation
Fecal microbiome-based machine learning model for diagnosis or risk prediction of Post Acute COVID-19 syndrome
Research completion
2022
Problem addressed

In order to help citizens fend off the epidemic and recover from COVID-19 and sequelae as soon as possible, we developed a non-invasive stool test for the diagnosis and risk prediction of "Long COVID" based on the fecal microbiome, thereby providing evidence for appropriate treatments or interventions.

Innovation
  • Cause of "Long COVID" is unclear.We found over 70% people in Hong Kong have "long COVID" after acute SARS-CoV-2 infection.
  • Long COVID can affect over 10 organs with more than 49 symptoms. Most common symptoms are fatigue, poor memory and hair loss.
  • There is a lack of diagnosis or risk prediction tool for long COVID.
Key impact
  • This is the World's first non-invasive stool test to predict long COVID symptoms.
  • This test has a high sensitivity of 95% and high specificity of 92%.
  • This test can detect different long COVID symptoms across multi-organs.
Application
  • People who have been infected with COVID-19 or are at risk of infection.

Patent

  • US patent COVID Multi-biome (1st Provisional Application No. 63/355,443, Filing date: 24 Jun 2022)

First Asia-based, leading International Microbiome Innovation Centre. 

Pioneering microbiome research leading to scientific discoveries and clinical applications of gut microbiota has set foot in the newly founded Microbiota I-Center (MagIC) in Hong Kong. Together with top-notch researchers, the center will focus on utilizing the human gut microbiome for the development of novel microbial biomarkers and personalized microbiome therapeutics. This approach sets a new frontier for the pharmaceutical, healthcare, and food industries in Hong Kong.

Enquiry
Related Innovations